2013.07.08 Polyprill Zinc Multi-Center Clinical Study Protocol Discussion Meeting

Release date:

2020-08-08

From July 6 to 7, 2013, a symposium was grandly held at the China World Hotel in Beijing to discuss the protocol for the "Multicenter, Randomized, Parallel-Controlled Clinical Study on Triple Therapy Combined with Polyprazin (3+P Therapy) for Helicobacter pylori-Associated Gastritis." The study was sponsored by Jilin Boda Weiye Pharmaceutical Co., Ltd., with Peking Union Medical College Hospital serving as the leading institution. Participating centers included Shanghai Renji Hospital, Jiangsu Provincial People's Hospital, Xiamen Zhongshan Hospital, the First Hospital of Jilin University, the First Affiliated Hospital of Nanchang University, Shandong Qilu Hospital, Xiangya Hospital, and the First Affiliated Hospital of Zhejiang University School of Medicine. A total of 17 experts from 11 participating centers attended the meeting to review and refine the preliminary draft of the trial protocol. Discussions focused on enhancing the trial design, improving the informed consent form, clarifying inclusion and exclusion criteria, defining key assessment metrics, and ensuring that all stakeholders—experts and investigators alike—are fully informed about the entire study process. This collaborative effort aims to make the "Triple Therapy Combined with Polyprazin (3+P Therapy) for Helicobacter pylori-Associated Gastritis" clinical study more rigorous, scientifically sound, and ethically compliant.

From July 6 to 7, 2013, a symposium was held grandly at the China World Hotel in Beijing to discuss the protocol for the "Multicenter, Randomized, Parallel-Controlled Clinical Study on Triple Therapy Combined with Polyprazin (3+P Therapy) for Helicobacter pylori-Associated Gastritis," sponsored by Jilin Boda Weiye Pharmaceutical Co., Ltd. and led by Peking Union Medical College Hospital, with participating institutions including Shanghai Renji Hospital, Jiangsu Provincial People's Hospital, Xiamen Zhongshan Hospital, the First Hospital of Jilin University, the First Affiliated Hospital of Nanchang University, Shandong Qilu Hospital, Xiangya Hospital, and the First Affiliated Hospital of Zhejiang University School of Medicine. A total of 17 participants from the 11 participating centers attended the discussion.
This meeting will focus on discussing the preliminary draft of the trial protocol for the "Multicenter, Randomized, Parallel-Controlled Clinical Study on Treating Helicobacter pylori-Related Gastritis with Triple Therapy Combined with Polyprazin (3+P Therapy)," aiming to further refine the study design, enhance the informed consent form, clarify inclusion and exclusion criteria as well as examination procedures, define efficacy evaluation standards, and ensure all experts and mentors are fully aware of the entire trial process. The goal is to make the protocol for the "Multicenter, Randomized, Parallel-Controlled Clinical Study on Treating Helicobacter pylori-Related Gastritis with Triple Therapy Combined with Polyprazin (3+P Therapy)" more rigorous, scientifically sound, and ethically compliant.